FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568344912> ?p ?o ?g. }

• W2568344912 endingPage "759" @default.
• W2568344912 startingPage "753" @default.
• W2568344912 abstract "The management of locally advanced pancreatic cancer (LAPC) is a major challenge. Although new drugs are available for the treatment of metastatic disease, the optimal treatment of non-metastatic cases remains controversial. The role of neoadjuvant therapy is still a question of debate in this setting. The aim of the study was to prospectively collect and analyse data on efficacy and safety of a modified FOLFIRINOX regimen in LAPC patients treated in a single institution. Another major objective was to assess the capability of FOLFIRINOX to render primary non-resectable cancer to resectable. No bolus fluorouracil was given and a 20% dose reduction of oxaliplatin and irinotecan was applied. Primary G-CSF prophylaxis was applied to prevent febrile neutropenia. Thirty-two patients (mean age 60.2 years, range: 40–77 years) have been enrolled into the study. All patients had ECOG performance status of 0 or 1. Best response to therapy was stable disease (SD) or partial regression (PR) in 18 (56.2%) and 6 (18.8%) cases. Two patients (6.3%) underwent surgical resection (100% R0). The most frequent grade 3/4 adverse events were nausea (18.8%), fatigue (12.5%) and diarrhea (12.5%). The incidence of severe neutropenia was 28.1%, with only one documented case of febrile neutropenia. The probability of disease progression was 25% and 50% after 75 and 160 days with 88.4% of possibility of disease progression after 500 days. OS probability was 92.1, 71.5% and 49.5% at 180-, 365 and 540 days. Our data does not support the capability of FOLFIRINOX to render primary non-resectable cancer to resectable. However, due to the high disease control rate observed, FOLFRINOX might be recommended as first line option for the palliative treatment of LAPC. Despite reduced chemotherapy doses significant toxicity has been seen." @default.
• W2568344912 created "2017-01-13" @default.
• W2568344912 creator A5033985179 @default.
• W2568344912 creator A5037254369 @default.
• W2568344912 creator A5039719390 @default.
• W2568344912 creator A5059468570 @default.
• W2568344912 creator A5069115105 @default.
• W2568344912 creator A5077887662 @default.
• W2568344912 creator A5081788714 @default.
• W2568344912 date "2017-01-06" @default.
• W2568344912 modified "2023-10-16" @default.
• W2568344912 title "Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience." @default.
• W2568344912 cites W1530374458 @default.
• W2568344912 cites W1967411786 @default.
• W2568344912 cites W1982150974 @default.
• W2568344912 cites W2022501291 @default.
• W2568344912 cites W2023377017 @default.
• W2568344912 cites W2027389238 @default.
• W2568344912 cites W2054625398 @default.
• W2568344912 cites W2110768657 @default.
• W2568344912 cites W2121059143 @default.
• W2568344912 cites W2121608920 @default.
• W2568344912 cites W2151253787 @default.
• W2568344912 cites W2168645047 @default.
• W2568344912 cites W2171950337 @default.
• W2568344912 cites W2187917981 @default.
• W2568344912 cites W2317504614 @default.
• W2568344912 cites W2323248054 @default.
• W2568344912 cites W2345822778 @default.
• W2568344912 cites W2467479187 @default.
• W2568344912 cites W2514008771 @default.
• W2568344912 cites W2520774580 @default.
• W2568344912 doi "https://doi.org/10.1007/s12253-016-0176-0" @default.
• W2568344912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28062950" @default.
• W2568344912 hasPublicationYear "2017" @default.
• W2568344912 type Work @default.
• W2568344912 sameAs 2568344912 @default.
• W2568344912 citedByCount "18" @default.
• W2568344912 countsByYear W25683449122018 @default.
• W2568344912 countsByYear W25683449122019 @default.
• W2568344912 countsByYear W25683449122020 @default.
• W2568344912 countsByYear W25683449122021 @default.
• W2568344912 countsByYear W25683449122022 @default.
• W2568344912 countsByYear W25683449122023 @default.
• W2568344912 crossrefType "journal-article" @default.
• W2568344912 hasAuthorship W2568344912A5033985179 @default.
• W2568344912 hasAuthorship W2568344912A5037254369 @default.
• W2568344912 hasAuthorship W2568344912A5039719390 @default.
• W2568344912 hasAuthorship W2568344912A5059468570 @default.
• W2568344912 hasAuthorship W2568344912A5069115105 @default.
• W2568344912 hasAuthorship W2568344912A5077887662 @default.
• W2568344912 hasAuthorship W2568344912A5081788714 @default.
• W2568344912 hasConcept C121608353 @default.
• W2568344912 hasConcept C126322002 @default.
• W2568344912 hasConcept C141071460 @default.
• W2568344912 hasConcept C143998085 @default.
• W2568344912 hasConcept C197934379 @default.
• W2568344912 hasConcept C2776694085 @default.
• W2568344912 hasConcept C2777063308 @default.
• W2568344912 hasConcept C2777148230 @default.
• W2568344912 hasConcept C2778850193 @default.
• W2568344912 hasConcept C2780210213 @default.
• W2568344912 hasConcept C2780259306 @default.
• W2568344912 hasConcept C2780962732 @default.
• W2568344912 hasConcept C2781413609 @default.
• W2568344912 hasConcept C526805850 @default.
• W2568344912 hasConcept C71924100 @default.
• W2568344912 hasConceptScore W2568344912C121608353 @default.
• W2568344912 hasConceptScore W2568344912C126322002 @default.
• W2568344912 hasConceptScore W2568344912C141071460 @default.
• W2568344912 hasConceptScore W2568344912C143998085 @default.
• W2568344912 hasConceptScore W2568344912C197934379 @default.
• W2568344912 hasConceptScore W2568344912C2776694085 @default.
• W2568344912 hasConceptScore W2568344912C2777063308 @default.
• W2568344912 hasConceptScore W2568344912C2777148230 @default.
• W2568344912 hasConceptScore W2568344912C2778850193 @default.
• W2568344912 hasConceptScore W2568344912C2780210213 @default.
• W2568344912 hasConceptScore W2568344912C2780259306 @default.
• W2568344912 hasConceptScore W2568344912C2780962732 @default.
• W2568344912 hasConceptScore W2568344912C2781413609 @default.
• W2568344912 hasConceptScore W2568344912C526805850 @default.
• W2568344912 hasConceptScore W2568344912C71924100 @default.
• W2568344912 hasIssue "4" @default.
• W2568344912 hasLocation W25683449121 @default.
• W2568344912 hasLocation W25683449122 @default.
• W2568344912 hasOpenAccess W2568344912 @default.
• W2568344912 hasPrimaryLocation W25683449121 @default.
• W2568344912 hasRelatedWork W1985988050 @default.
• W2568344912 hasRelatedWork W2206740068 @default.
• W2568344912 hasRelatedWork W2599910524 @default.
• W2568344912 hasRelatedWork W2761790232 @default.
• W2568344912 hasRelatedWork W2910998150 @default.
• W2568344912 hasRelatedWork W3030047436 @default.
• W2568344912 hasRelatedWork W3045328550 @default.
• W2568344912 hasRelatedWork W4214739478 @default.
• W2568344912 hasRelatedWork W4282037277 @default.
• W2568344912 hasRelatedWork W4380150473 @default.
• W2568344912 hasVolume "23" @default.

• next